StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Dexlansoprazole

HCID 9578005
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
138530-94-6
Standard-SMILES
Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1
InChIKey
MJIHNNLFOKEZEW-RUZDIDTESA-N
Summenformel
C16H14F3N3O2S
Durchschnittliche Molmasse
369,4 g/mol
Monoisotopische Masse
369,07588236

Überblick

Dexlansoprazole is a sulfoxide and a member of benzimidazoles.

Namen und Bezeichner

Bevorzugter Name
Dexlansoprazole
IUPAC
2-[(R)-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylsulfinyl]-1H-benzimidazole
Englischer Name
R-(+)-Lansoprazole
Summenformel
C16H14F3N3O2S
Molmasse
369.36

Namen und Synonyme

dexlansoprazole(R)-Lansoprazole138530-94-6KapidexdexilantDexilant Solutabr-lansoprazoleTAK-390TAK 390Lansoprazole, (r)-dexlansoprazolT 168390
Weitere Namen anzeigen
D-lansoprazoleDexlansaprazoleDexlanzoprazoleT 168390,TAK 390(+)-LansoprazoleR-(+)-LansoprazoleD4-(R)-Lansoprazole
UYE4T5I70XT-168390NSC-758710TAK-390MR2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole1H-Benzimidazole, 2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-(+)-2-((R)-((3-METHYL-4-(2,2,2-TRIFLUOROETHOXY)PYRIDIN-2-YL)METHYL)SULFINYL)-1H-BENZIMIDAZOLE

Datenbank-Bezeichner

CAS
138530-94-6
PubChem CID
9578005
ChEMBL
CHEMBL1201863
ChEBI
CHEBI:135931
UNII
UYE4T5I70X

Eigenschaften

Berechnete Struktureigenschaften

XLogP
2,8
Polarare Oberfläche (TPSA)
87,1 Ų
H-Brücken-Donoren
1
H-Brücken-Akzeptoren
8
Frei drehbare Bindungen
5
Schwere Atome
25
Formalladung
0
Komplexität
480

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Alimentary tract and metabolism -> Drugs for acid related disorders

Pharmaceuticals -> Used in Switzerland

Human Drugs · 4 Einträge

Breast Feeding; Lactation; Milk, Human; Anti-Ulcer Agents; Gastrointestinal Agents; Proton Pump Inhibitors

Breast Feeding; Lactation; Milk, Human; Anti-Ulcer Agents; Gastrointestinal Agents; Proton Pump Inhibitors

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section165.34 Ų [M+H-H2O]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physikochemische Eigenschaften

Schmelzpunkt
66 · 66-68C
Siedepunkt
555.8 · 555.8±60.0 °C(Predicted)
Dichte
1.5 · 1.50±0.1 g/cm3(Predicted)
storage temp.
2 · Sealed in dry,2-8°C
Löslichkeit

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H315 (33.3%): Causes skin irritation [Warning Skin corrosion/irritation]

P203, P260, P261, P264, P264+P265, P271, P272, P280, P302+P352, P304+P340, P305+P351+P338, P318, P319, P321, P332+P317, P333+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 3 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxikologische Informationen

Drug Induced Liver Injury · 6 Einträge

Drug Induced Liver Injury Rank (DILIrank 2.0)

Dexlansoprazole

vLess-DILI-concern

4

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation · 2 Einträge

◉ Summary of Use during Lactation

◉ Summary of Use during Lactation

Sicherheitsdaten

wgk
WGK 3
Speicherklasse
11 - Combustible Solids

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 2 Einträge

A - Alimentary tract and metabolism

QA - Alimentary tract and metabolism

Protein BindingPlasma protein binding of dexlansoprazole ranged from 96 to 99% in healthy subjects and was independent of concentration from 0.01 to 20 mcg/mL.
Pharmacodynamics · 1 Eintrag

Dexlansoprazole is a proton pump inhibitor (PPI) that suppresses both basal and stimulated gastric acid secretion. PPIs are associated with a risk for a rebound effect and a short-term increase in hypersecretion; thus, such risk cannot be excluded with dexlansoprazole. With long-term use, PPIs are also associated with a risk of increased susceptibility to bacterial infections, vitamin B12 and iron deficiency, and hypomagnesemia and hypocalcemia, possibly leading to osteoporosis and bone fractures. Dexlansoprazole is reported to interfere with the secretin stimulation test and create false positive urine screening tests for tetrahydrocannabinol. Dexlansoprazole can increase gastrin levels, which can cause enterochromaffin-like cell hyperplasia and increase serum CgA levels. Increased CgA levels may cause false positive results in diagnostic investigations for neuroendocrine tumours.

Mechanism of Action · 1 Eintrag

Dexlansoprazole suppresses gastric acid secretion by blocking the final step of acid production. It inhibits the H/K ATPase at the secretory surface of the gastric parietal cell, which is involved in the secretion of hydrochloric acid. H/K ATPase is a proton pump responsible for hydrolyzing ATP and exchanging H<sup>+</sup> ions from the cytoplasm for K<sup>+</sup> ions in the secretory canaliculus: this action results in hydrochloric acid secretion into the gastric lumen.

Biological Half-LifeDexlansoprazole is eliminated with a half-life of approximately one to two hours.
Metabolism/Metabolites · 2 Einträge

Dexlansoprazole is extensively metabolized in the liver. It undergoes oxidation and reduction, followed by subsequent sulfation, glucuronidation, and glutathione conjugation to form inactive metabolites. Oxidative metabolites are formed from CYP2C19-mediated hydroxylation and CYP3A4-mediated oxidation to the sulfone. CYP2C19 is a polymorphic liver enzyme which exhibits three phenotypes in the metabolism of CYP2C19 substrates: extensive metabolizers (*1/*1), intermediate metabolizers (*1/mutant) and poor metabolizers (mutant/mutant). Dexlansoprazole is the major circulating component in plasma regardless of CYP2C19 metabolizer status. In CYP2C19 intermediate and extensive metabolizers, the major plasma metabolites are 5-hydroxy dexlansoprazole and its glucuronide conjugate, while in CYP2C19 poor metabolizers dexlansoprazole sulfone is the major plasma metabolite.

Zugehörige Reaktionen

33
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 16931
HRID 16931als Produkt
Reaktionsgleichung von HRID 16932
HRID 16932als Produkt
Reaktionsgleichung von HRID 335395
HRID 335395als Produkt
Reaktionsgleichung von HRID 335396
HRID 335396als Produkt
Reaktionsgleichung von HRID 432787
HRID 432787als Produkt
Reaktionsgleichung von HRID 432788
HRID 432788als Produkt
Reaktionsgleichung von HRID 495678
HRID 495678als Produkt
Reaktionsgleichung von HRID 495679
HRID 495679als Produkt
ZurückSeite 1 von 5

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
EC Number
688-930-9
Nikkaji
J3.802.358F
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
9.56 · 9.56±0.10(Predicted)
Farbe
Off-White to Dark Brown
Stabilität
Hygroscopic
InChI
InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22)/t25-/m1/s1
InChIKey
MJIHNNLFOKEZEW-RUZDIDTESA-N
SMILES
C1([S@@](CC2=NC=CC(OCC(F)(F)F)=C2C)=O)NC2=CC=CC=C2N=1

Lansoprazole has known human metabolites that include Lansoprazole Sulfone and 5-Hydroxylansoprazole.

FDA Pharmacological Classification · 6 Einträge

UYE4T5I70X

DEXLANSOPRAZOLE

Established Pharmacologic Class [EPC] - Proton Pump Inhibitor

Mechanisms of Action [MoA] - Proton Pump Inhibitors

Dexlansoprazole is a Proton Pump Inhibitor. The mechanism of action of dexlansoprazole is as a Proton Pump Inhibitor.

DEXLANSOPRAZOLE

MeSH Pharmacological Classification · 2 Einträge

Various agents with different action mechanisms used to treat or ameliorate PEPTIC ULCER or irritation of the gastrointestinal tract. This has included ANTIBIOTICS to treat HELICOBACTER INFECTIONS; HISTAMINE H2 ANTAGONISTS to reduce GASTRIC ACID secretion; and ANTACIDS for symptomatic relief.

Compounds that inhibit H(+)-K(+)-EXCHANGING ATPASE. They are used as ANTI-ULCER AGENTS and sometimes in place of HISTAMINE H2 ANTAGONISTS for GASTROESOPHAGEAL REFLUX.

Absorption, Distribution and Excretion · 4 Einträge

The dual delayed-release formulation of dexlansoprazole results in a plasma concentration-time profile with two distinct peaks; the first peak occurs one to two hours after administration, followed by a second peak within four to five hours. About 25% of the dose is released at the pH level of 5.5 in the proximal duodenum, while the other 75% is released in the distal small intestine at the pH level of 6.75. After oral administration of dexlansoprazole 30 or 60 mg to healthy subjects and symptomatic GERD patients, mean Cmax and AUC values of dexlansoprazole increased approximately dose-proportionally. Following administration of 30 mg in healthy adults, the mean (%CV) Cmax and AUC were 658 (40%) ng/mL and 3275 (47%) ng x h/mL, respectively. At a dose of 60 mg, the mean (%CV) Cmax and AUC were 1397 (51%) ng/mL and 6529 (60%) ng x h/mL, respectively. In healthy subjects, food increased Cmax by 12 to 55% and AUC by 9 to 37%. The effect of food on Tmax varied, as both an increase and a decrease was observed.

Dexlansoprazole does not appear to be eliminated unchanged in the urine. Following the administration of [14C] dexlansoprazole to six healthy male subjects, approximately 50.7% (standard deviation (SD): 9.0%) of the administered radioactivity was excreted in urine and 47.6% (SD: 7.3%) in the feces.

The apparent volume of distribution (Vz/F) after multiple doses in symptomatic GERD patients was 40 L.

Apparent clearance (CL/F) in healthy subjects was 11.4 to 11.6 L/hour, respectively, after five days of 30 or 60 mg once daily administration.

Anwendungen · 2 Einträge

BeschreibungThe mechanism of PPIs involves the irreversible binding to the hydrogen/potassium adenosine triphosphatase enzyme system, commonly referred to as the gastric proton pump, of the gastric parietal cell. As the last stage in gastric acid secretion, blockade of the gastric proton pump is an effective treatment for a variety of diseases requiring acid suppression, such as heartburn, peptic ulcers, and GERD. Dexlansoprazole is the latest PPI to hit the market, joining the ranks of omeprazole, rabeprazole, pantoprazole, esomeprazole, and lansoprazole, and is the Renantiomer of the racemic lansoprazole. Compared to its predecessors, dexlansoprazole exhibits improved pharmacokinetics with slower clearance and longer terminal half-life. In addition, dexlansoprazole utilizes a novel DDR technology; drug release is optimized through the use of granules with different pH-dependent dissolution profiles, thereby providing an initial release in the proximal small intestine within 1-2 h of administration followed by a subsequent release at distal regions of the small intestine several hours later. With its longer duration of action culminating in more effective acid suppression, dexlansoprazole may have an advantage over conventional PPIs that possess single release formulations (immediate or delayed). Similar to all PPIs, dexlansoprazole is a prodrug that consists of pyridine and benzimidazole rings with a latent sulfenamide moiety. In order to form the disulfide bond with cysteine residues of the proton pump, dexlansoprazole must be activated through two protonations followed by a spontaneous rearrangement to unmask the sulfenamide.

VerwendenThe R-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

2-[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methylthio-1H-benzimidazoleLansoprazole(S)-LansoprazoleDiethyltartratCumolhydroperoxidN,N-Diethylethanamin